Benjamin Hadida – Translating the potential of . Faecalibacterium prausnitzii In Crohn’s Disease to the clinical Sstage

Developing a pipeline of next generation immunotherapies for immune-mediated diseases and cancer by harnessing the association of F. prausnitzil with relapse-free survival in patients with Crohn’s Disease: a single-strain approach that can complement standard of care treatment through induction of IL-10, resulting in maintainenance of tolerance and disease remission. Benjamin Hadida (Exeliom Biosciences) discussed during the Microbiome Connect: USA 2022 how to validate innovative clinical trial design and overcome challenges of robust-large scale manufacturing.